Clinical and morphological characteristics of neuroendocrine tumors: clinical experience
https://doi.org/10.17650/2313-805X-2017-4-1-35-39
Abstract
Currently, treatment and diagnostics of neuroendocrine tumors are associated with a number of problems, including absence of a registry for these diseases. The article considers the main approaches and problems of immunohistochemical diagnostics of neuroendocrine tumors.
About the Authors
G. A. Raskin
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of Russia
Russian Federation
70 Leningradskaya St., Pesochnyy Settlement, Saint-Petersburg 197758, Russia
Russian Federation
70 Leningradskaya St., Pesochnyy Settlement, Saint-Petersburg 197758, Russia
A. K. Ivanova
City Clinical Oncological Dispensary
Russian Federation
3/5 2nd Berezovaya Alleya, Saint-Petersburg 197022, Russia
Russian Federation
3/5 2nd Berezovaya Alleya, Saint-Petersburg 197022, Russia
R. V. Orlova
City Clinical Oncological Dispensary
Saint-Petersburg State University
Russian Federation
Russian Federation
3/5 2nd Berezovaya Alleya, Saint-Petersburg 197022, Russia
7–9 Universitetskaya St., Saint-Petersburg 199034, Russia
Medical Faculty
References
1. Горбунова В.А. Нейроэндокринные опухоли. Общие принципы диагностики и лечения. М.: Кодекс, 2015. 456 с. [Gorbunova V.A. Neuroendocrine tumors. General principles of diagnostics and treatment. Moscow: Kodeks, 2015. 456 p. (In Russ.)].
2. Симоненко В.Б., Дудин П.А., Маканин М.А. Нейроэндокринные опухоли. М.: ГЭОТАР- Медиа, 2010. 237 с. [Simonenko V.B., Dudin P.A., Makanin M.A. Neuroendocrine tumors. Moscow: GEOTAR-Media, 2010. 237 p. (In Russ.)].
3. WHO classification of tumors the digestive system. Ed. by F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise. Lyon: IARC Press, 2010.
4. WHO classification of tumours of the lung, pleura, thymus and heart. Ed. by W.D. Travis, E. Brambilla, A.P. Burke et al. Lyon: IARC Press, 2015.
5. Sorbye H., Welin S., Langer S.W. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013;24(1): 152–60.
6. Khan S., Luong T.V., Watkins J. et al. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer 2013;108(9):1838–45.
7. Scarpa A., Mantovani W., Capelli P. et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010;23(6):824–33.
8. Arco D.D., Pérez D., Medina O. et al. Reliability of Ki-67 determination in FNA samples for grading pancreatic neuroendocrine tumors. Endocr Pathol 2016;27(4):276–83.
9. Farrell J.M., Pang J.C., Kim G.E., Tabatabai Z.L. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytopathol 2014;122(10): 770–8.
10. Kleist B., Poetsch M. Neuroendocrine differentiation: The mysterious fellow of colorectal cancer. World J Gastroenterol 2015;21(41):11740–7.
11. Sentani K., Oue N., Noguchi T. et al. Immunostaining of gastric cancer with neuroendocrine differentiation: Reg IV-positive neuroendocrine cells are associated with gastrin, serotonin, pancreatic polypeptide and somatostatin. Pathol Int 2010;60(4):291–7.
12. Swarts D.R., van Suylen R.J., den Bakker M.A. et al. Interobserver variability for the WHO classification of pulmonary carcinoids. Am J Surg Pathol 2014;38(10):1429–36.
13. Takeuchi K., Togashi Y., Kamihara Y. et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALKpositive lung cancer (AF-001JP study). Ann Oncol 2016;27(1):185–92.
14. WHO classification of tumours of the breast. Ed. by S.R. Lakhani, I.O. Ellis, S.J. Schnitt et al. Lyon: IARC Press, 2012.
15. Gao L.X., Liu G., Li L. et al. Neuroendocrine carcinoma of breast: a study of tumor morphology and subtyping. Zhonghua Bing Li Xue Za Zhi 2011;40(9):604–9.
16. WHO classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Ed. by F.A. Tavassoli, P. Devilee. Lyon: IARC Press, 2003.
17. Miremadi A., Pinder S.E., Lee A.H. et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002;40(3):215–22.
18. Inno A., Bogina G., Turazza M. et al. Neuroendocrine carcinoma of the breast: current evidence and future perspectives. Oncologist 2016;21(1):28–32.
19. Wei B., Ding T., Xing Y. et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 2010;116(19):4463–73.
20. Tian Z., Wei B., Tang F. et al. Prognosticsignificance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol 2011;42(8):1169–77.
21. Kwon S.Y., Bae Y.K., Gu M.J. et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 2014;64(5):647–59.
Review
For citations:
Raskin G.A., Ivanova A.K., Orlova R.V. Clinical and morphological characteristics of neuroendocrine tumors: clinical experience. Advances in Molecular Oncology. 2017;4(1):35-39. (In Russ.) https://doi.org/10.17650/2313-805X-2017-4-1-35-39
Views:
2395
Email this article 